Every material Form 8-K MESA LABORATORIES INC /CO/ has filed with the SEC since June 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Mesa Laboratories approved a restructuring program that eliminates about 40 positions, mainly in its Clinical Genomics division, and exits its Hamburg, Germany facility when its lease expires in February 2027. The company expects a net annualized cost reduction of about $5.0 million after reinvestment, but says Clinical Genomics revenue will be lower as it narrows its focus to pharmacogenomics and oncology.
Estimated total pre-tax charges of $2.6 million to $3.4 million, mainly in the second half of fiscal year 2027
Expected related cash expenditures of $2.9 million to $3.7 million, substantially all over the next 12 months
Savings plan to reduce annualized operating costs by about $9.3 million, with about $4.3 million reinvested
Company will report second quarter fiscal year 2027 results and provide fiscal 2027 guidance on November 9, 2026
Mesa Laboratories reported results for the quarter ended June 30, 2026, its fiscal first quarter of 2027. Revenue rose 1.0% to $60.1 million and operating income rose 129% to $7.0 million, but net income fell 40.3% to $2.8 million, or $0.49 per diluted share, because of nonoperating expense compared with nonoperating income in the prior-year period. Full-year guidance is due in November with first-half results.
Revenue was $60.1 million, up 1.0%; core organic revenue growth was 0.4%.
Operating income rose 129% to $7.0 million; net income fell 40.3% to $2.8 million, or $0.49 per diluted share.
Adjusted operating income excluding unusual items rose 19.5% to $15.4 million, or 25.6% of revenue.
The company repaid $8.7 million of debt and reported a Total Net Leverage Ratio of 1.85, below its 2.0 target.
Mesa Laboratories appointed Lyndsey Crennen as Chief Accounting Officer, with the board approving the appointment on June 11, 2026. She has been with Mesa since 2018, most recently as Corporate Controller, and her employment agreement is expected to be signed on or about June 26, 2026.
Lyndsey Crennen, age 41, is appointed Chief Accounting Officer; the board approved the appointment on June 11, 2026.
Expected annual base salary of $325,000, with a short-term bonus opportunity of 40% of base salary.
Long-term incentive plan target award value of $300,000 per year.
Employment agreement expected on or about June 26, 2026, filed as Exhibit 10.1.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MESA LABORATORIES INC /CO/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →